Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366191657> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4366191657 endingPage "S270" @default.
- W4366191657 startingPage "S270" @default.
- W4366191657 abstract "Drug hypersensitivity reactions (DHR) have potential for significant morbidity and mortality, without clear treatment for severe reactions. Standard of care is to immediately stop potential culprit drug(s) and to never rechallenge. However, the culprit drug and/or whether the patient would develop a severe form of DHR is unknown. Even if the culprit is clear and reaction severe, the patient may have no alternative for their underlying disease. Analysis of bulk transcriptional profiling of patient skin specimens suggested activation of JAK/STAT pathways in mild (morbilliform drug eruption) and severe (Stevens-Johnson Syndrome/toxic epidermal necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms) DHR, with a pattern consistent with both IFNg and IL2Rgc signaling. Immunohistochemical staining for activated forms of protein confirmed increased expression and activation of JAK1, 2 and 3, and STAT1 and 2 in all three forms of DHR. Two cancer patients developed DHR concerning for risk of progression to severe disease attributed to their anti-cancer therapy. Cancer treatment was stopped but neither patient had an alternative available. Both patients were successfully prophylaxed with a non-selective JAK inhibitor, ruxolitinib, prior to reinitiating the suspected culprit drug. In both cases, the patients received their anti-cancer therapy without reacting. One patient subsequently completed chemotherapy, underwent surgical tumor resection and is without evidence of disease over one year later. The other patient successfully tapered off ruxolitinib after 5 months while remaining on targeted anti-cancer therapy with 2 months follow up to-date. Further research is necessary to expand and reproduce these findings, but the data support that pharmacologically inhibiting JAK signaling may prevent DHR." @default.
- W4366191657 created "2023-04-19" @default.
- W4366191657 creator A5002898622 @default.
- W4366191657 creator A5010053025 @default.
- W4366191657 creator A5013626591 @default.
- W4366191657 creator A5016100032 @default.
- W4366191657 creator A5044521843 @default.
- W4366191657 creator A5055001787 @default.
- W4366191657 creator A5063282219 @default.
- W4366191657 creator A5074531689 @default.
- W4366191657 creator A5083853236 @default.
- W4366191657 creator A5090359551 @default.
- W4366191657 date "2023-05-01" @default.
- W4366191657 modified "2023-09-27" @default.
- W4366191657 title "1573 JAK inhibition may prevent drug hypersensitivity reactions" @default.
- W4366191657 doi "https://doi.org/10.1016/j.jid.2023.03.1591" @default.
- W4366191657 hasPublicationYear "2023" @default.
- W4366191657 type Work @default.
- W4366191657 citedByCount "0" @default.
- W4366191657 crossrefType "journal-article" @default.
- W4366191657 hasAuthorship W4366191657A5002898622 @default.
- W4366191657 hasAuthorship W4366191657A5010053025 @default.
- W4366191657 hasAuthorship W4366191657A5013626591 @default.
- W4366191657 hasAuthorship W4366191657A5016100032 @default.
- W4366191657 hasAuthorship W4366191657A5044521843 @default.
- W4366191657 hasAuthorship W4366191657A5055001787 @default.
- W4366191657 hasAuthorship W4366191657A5063282219 @default.
- W4366191657 hasAuthorship W4366191657A5074531689 @default.
- W4366191657 hasAuthorship W4366191657A5083853236 @default.
- W4366191657 hasAuthorship W4366191657A5090359551 @default.
- W4366191657 hasBestOaLocation W43661916571 @default.
- W4366191657 hasConcept C121608353 @default.
- W4366191657 hasConcept C126322002 @default.
- W4366191657 hasConcept C141071460 @default.
- W4366191657 hasConcept C143998085 @default.
- W4366191657 hasConcept C16005928 @default.
- W4366191657 hasConcept C2778826181 @default.
- W4366191657 hasConcept C2779134260 @default.
- W4366191657 hasConcept C2780035454 @default.
- W4366191657 hasConcept C2780664588 @default.
- W4366191657 hasConcept C2781190966 @default.
- W4366191657 hasConcept C500558357 @default.
- W4366191657 hasConcept C71924100 @default.
- W4366191657 hasConcept C98274493 @default.
- W4366191657 hasConceptScore W4366191657C121608353 @default.
- W4366191657 hasConceptScore W4366191657C126322002 @default.
- W4366191657 hasConceptScore W4366191657C141071460 @default.
- W4366191657 hasConceptScore W4366191657C143998085 @default.
- W4366191657 hasConceptScore W4366191657C16005928 @default.
- W4366191657 hasConceptScore W4366191657C2778826181 @default.
- W4366191657 hasConceptScore W4366191657C2779134260 @default.
- W4366191657 hasConceptScore W4366191657C2780035454 @default.
- W4366191657 hasConceptScore W4366191657C2780664588 @default.
- W4366191657 hasConceptScore W4366191657C2781190966 @default.
- W4366191657 hasConceptScore W4366191657C500558357 @default.
- W4366191657 hasConceptScore W4366191657C71924100 @default.
- W4366191657 hasConceptScore W4366191657C98274493 @default.
- W4366191657 hasIssue "5" @default.
- W4366191657 hasLocation W43661916571 @default.
- W4366191657 hasOpenAccess W4366191657 @default.
- W4366191657 hasPrimaryLocation W43661916571 @default.
- W4366191657 hasRelatedWork W1550862849 @default.
- W4366191657 hasRelatedWork W1565150316 @default.
- W4366191657 hasRelatedWork W1986343171 @default.
- W4366191657 hasRelatedWork W2986450741 @default.
- W4366191657 hasRelatedWork W4220716815 @default.
- W4366191657 hasRelatedWork W4220805039 @default.
- W4366191657 hasRelatedWork W4226146509 @default.
- W4366191657 hasRelatedWork W4299517282 @default.
- W4366191657 hasRelatedWork W4366524189 @default.
- W4366191657 hasRelatedWork W62381600 @default.
- W4366191657 hasVolume "143" @default.
- W4366191657 isParatext "false" @default.
- W4366191657 isRetracted "false" @default.
- W4366191657 workType "article" @default.